- Home
- TECX vs NEWT Comparison
TECX vs NEWT Comparison
Compare TECX & NEWT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TECX
- NEWT
- Stock Information
- Founded
- TECX 2019
- NEWT 1998
- Country
- TECX United States
- NEWT United States
- Employees
- TECX N/A
- NEWT N/A
- Industry
- TECX
- NEWT Major Banks
- Sector
- TECX
- NEWT Finance
- Exchange
- TECX Nasdaq
- NEWT Nasdaq
- Market Cap
- TECX 334.4M
- NEWT 335.7M
- IPO Year
- TECX 2018
- NEWT N/A
- Fundamental
- Price
- TECX $19.76
- NEWT $10.38
- Analyst Decision
- TECX Buy
- NEWT Hold
- Analyst Count
- TECX 6
- NEWT 4
- Target Price
- TECX $72.40
- NEWT $14.00
- AVG Volume (30 Days)
- TECX 203.0K
- NEWT 314.5K
- Earning Date
- TECX 05-08-2025
- NEWT 05-06-2025
- Dividend Yield
- TECX N/A
- NEWT 7.42%
- EPS Growth
- TECX N/A
- NEWT 27.59
- EPS
- TECX N/A
- NEWT 1.92
- Revenue
- TECX N/A
- NEWT $352,584,000.00
- Revenue This Year
- TECX N/A
- NEWT N/A
- Revenue Next Year
- TECX N/A
- NEWT $15.38
- P/E Ratio
- TECX N/A
- NEWT $5.33
- Revenue Growth
- TECX N/A
- NEWT 23.06
- 52 Week Low
- TECX $1.40
- NEWT $9.12
- 52 Week High
- TECX $61.07
- NEWT $15.49
- Technical
- Relative Strength Index (RSI)
- TECX 49.14
- NEWT 46.89
- Support Level
- TECX $17.56
- NEWT $9.62
- Resistance Level
- TECX $21.99
- NEWT $10.26
- Average True Range (ATR)
- TECX 1.96
- NEWT 0.43
- MACD
- TECX 0.21
- NEWT 0.04
- Stochastic Oscillator
- TECX 46.15
- NEWT 55.77
About TECX Tectonic Therapeutic Inc. Common Stock
Tectonic Therapeutic Inc is a biotechnology company focused on the discovery and development of therapeutic proteins and antibodies that modulate the activity of GPCRs. Its technology platform called GEODe, Tectonic is focused on developing biologic medicines that overcome the existing challenges of GPCR-targeted drug discovery to modify the course of disease. Company focus on areas of important unmet medical need, often where therapeutic options are poor or nonexistent, and where new medicines have the potential to improve patient quality of life or extend duration of life. Pipeline includes TX000045, Group 2 PH, TX2100: GPCR Antagonist for Hereditary Hemorrhagic Telangiectasia (HHT), Fibrosis.
About NEWT NewtekOne Inc.
NewtekOne Inc is a financial holding company engaged in providing financial solutions, It has developed a financial and technology-based business model that enables itself to acquire and process its clients in a very cost-effective manner. This capability is supported in large part by NewTracker, its patented prospect management technology software, that will allow NewtekOne clients to easily interact with NewtekOne subject matter experts in the areas of Banking, Lending, Payments, Technology, Payroll, and Insurance. It offers NewtekOne's clients a single online dashboard to access all of NewtekOne's business and financial solutions. It has four reportable segments Banking, Technology, NSBF, and Payments.